IE910579A1 - Novel protein compositions - Google Patents

Novel protein compositions

Info

Publication number
IE910579A1
IE910579A1 IE057991A IE57991A IE910579A1 IE 910579 A1 IE910579 A1 IE 910579A1 IE 057991 A IE057991 A IE 057991A IE 57991 A IE57991 A IE 57991A IE 910579 A1 IE910579 A1 IE 910579A1
Authority
IE
Ireland
Prior art keywords
insulin
iii
ins
general formula
pharmaceutical composition
Prior art date
Application number
IE057991A
Other languages
English (en)
Original Assignee
Novo Nordisk As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk As filed Critical Novo Nordisk As
Publication of IE910579A1 publication Critical patent/IE910579A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/52—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an inorganic compound, e.g. an inorganic ion that is complexed with the active ingredient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Inorganic Chemistry (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Chairs For Special Purposes, Such As Reclining Chairs (AREA)
IE057991A 1990-02-21 1991-02-20 Novel protein compositions IE910579A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DK045590A DK45590D0 (Direct) 1990-02-21 1990-02-21

Publications (1)

Publication Number Publication Date
IE910579A1 true IE910579A1 (en) 1991-08-28

Family

ID=8093754

Family Applications (1)

Application Number Title Priority Date Filing Date
IE057991A IE910579A1 (en) 1990-02-21 1991-02-20 Novel protein compositions

Country Status (12)

Country Link
EP (1) EP0516704B1 (Direct)
JP (1) JPH05503940A (Direct)
AU (1) AU641991B2 (Direct)
CA (1) CA2075982A1 (Direct)
DE (1) DE69100626D1 (Direct)
DK (1) DK45590D0 (Direct)
HU (1) HUT63858A (Direct)
IE (1) IE910579A1 (Direct)
NZ (1) NZ237176A (Direct)
PT (1) PT96841A (Direct)
WO (1) WO1991012817A1 (Direct)
ZA (1) ZA911279B (Direct)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9316895D0 (en) * 1993-08-13 1993-09-29 Guy S And St Thomas Hospitals Hepatoselective insulin analogues
US6342225B1 (en) 1993-08-13 2002-01-29 Deutshces Wollforschungsinstitut Pharmaceutical active conjugates
US6869930B1 (en) 1993-09-17 2005-03-22 Novo Nordisk A/S Acylated insulin
US6011007A (en) * 1993-09-17 2000-01-04 Novo Nordisk A/S Acylated insulin
DK0792290T3 (da) * 1993-09-17 2001-10-01 Novo Nordisk As Acyleret insulin
US6251856B1 (en) 1995-03-17 2001-06-26 Novo Nordisk A/S Insulin derivatives
US6451762B1 (en) 1997-10-24 2002-09-17 Novo Nordisk A/S Aggregates of human insulin derivatives
WO2005012347A2 (en) 2003-08-05 2005-02-10 Novo Nordisk A/S Novel insulin derivatives
ES2472421T3 (es) 2003-08-05 2014-07-01 Novo Nordisk A/S Nuevos derivados de insulina
WO2006082204A1 (en) 2005-02-02 2006-08-10 Novo Nordisk A/S Insulin derivatives
DK1969004T3 (da) 2005-12-28 2011-11-28 Novo Nordisk As Insulinsammensætninger og metode til at lave en sammensætning
JP5550338B2 (ja) 2006-07-31 2014-07-16 ノボ・ノルデイスク・エー／エス ペグ化持続型インスリン
EP2404934A1 (en) 2006-09-22 2012-01-11 Novo Nordisk A/S Protease resistant insulin analogues
JP5496082B2 (ja) 2007-04-30 2014-05-21 ノボ・ノルデイスク・エー／エス タンパク質組成物を乾燥させる方法、乾燥タンパク質組成物、及び乾燥タンパク質を含有する薬学的組成物
CN101677947B (zh) 2007-06-13 2013-07-17 诺沃-诺迪斯克有限公司 包含胰岛素衍生物的药物制剂
CN101970477B (zh) 2008-03-14 2014-12-31 诺沃-诺迪斯克有限公司 蛋白酶稳定的胰岛素类似物
AU2009226910B2 (en) 2008-03-18 2014-02-06 Novo Nordisk A/S Protease stabilized, acylated insulin analogues
MX2011004357A (es) 2008-10-30 2011-05-23 Novo Nordisk As Tratamiento de diabetes mellitus utilizando inyecciones de insulina con una frecuencia de inyeccion menor que a diario.
JP6049625B2 (ja) 2010-10-27 2016-12-21 ノヴォ ノルディスク アー／エス 様々な注射間隔を用いて施されるインスリン注射を使用する、真性糖尿病の治療
BR112014025132A2 (pt) 2012-04-11 2017-07-11 Novo Nordisk As formulações de insulina
EP2991672A1 (en) 2013-04-30 2016-03-09 Novo Nordisk A/S Novel administration regime
KR20160065126A (ko) 2013-10-07 2016-06-08 노보 노르디스크 에이/에스 인슐린 유사체의 신규한 유도체
KR102580007B1 (ko) 2016-12-16 2023-09-19 노보 노르디스크 에이/에스 인슐린 함유 약제학적 조성물
US10335464B1 (en) 2018-06-26 2019-07-02 Novo Nordisk A/S Device for titrating basal insulin
JP7518149B2 (ja) 2019-07-12 2024-07-17 ノヴォ ノルディスク アー／エス 高濃度インスリン製剤

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE971500C (de) * 1950-11-22 1959-02-05 Organon Nv Verfahren zur Herstellung von Insulin-Suspensionen mit verlaengerter Wirkung
DE1107374B (de) * 1958-01-31 1961-05-25 Organon Nv Verfahren zur Herstellung eines Insulin-Praeparates

Also Published As

Publication number Publication date
EP0516704A1 (en) 1992-12-09
AU7337891A (en) 1991-09-18
HUT63858A (en) 1993-10-28
CA2075982A1 (en) 1991-08-22
AU641991B2 (en) 1993-10-07
PT96841A (pt) 1991-11-29
NZ237176A (en) 1991-12-23
DE69100626D1 (de) 1993-12-16
WO1991012817A1 (en) 1991-09-05
JPH05503940A (ja) 1993-06-24
EP0516704B1 (en) 1993-11-10
DK45590D0 (Direct) 1990-02-21
ZA911279B (en) 1991-10-30
HU9202721D0 (en) 1992-12-28

Similar Documents

Publication Publication Date Title
EP0516704B1 (en) Novel insulin compositions
AU2004251625B2 (en) Synthesis of high molecular weight iron-saccharidic complexes
US5456922A (en) Water dispersible and water soluble carbohydrate polymer compositions for parenteral administration of growth hormone
DE3880346T2 (de) Insulinderivate.
US4877778A (en) Method of enhancing lipophile transport using cyclodextrin derivatives
Zhang et al. Polymer–covalent organic frameworks composites for glucose and PH dual‐responsive insulin delivery in mice
EP0855913B1 (en) Iron dextran formulations
KR890004687B1 (ko) 생물학적 활성 서방출성 조성물
CZ85790A3 (en) Novel preparations containing associates of hyaluronic acid, and process for preparing thereof
EP2943216B1 (en) Modified ace2 polypeptides
SA520420276B1 (ar) تركيبات صيدلية تحتوي على الأنسولين
EP2496213B1 (en) Pharmaceutical solution of non covalently bound albumin and acylated insulin
CA1335924C (en) Mixed crystals of insulin and insulin derivatives, a process for the preparation of these mixed crystals, pharmaceutical agents containing these mixed crystals, and the use thereof for the treatment of diabetes mellitus
ZA200600846B (en) Novel insulin derivatives
CN118203658A (zh) 一种重组抗Claudin18.2全人源单克隆抗体注射液制剂及制备方法
PT93366A (pt) Processo para a preparacao de novas insulinas glicosiladas especificamente e decomposicoes farmaceuticas que as contem
CS209458B2 (en) Method of making the complex of the insuline salt with the protamine
Enriquez et al. Conjugation of adenine arabinoside 5'-monophosphate to arabinogalactan: synthesis, characterization, and antiviral activity
KR20100019979A (ko) 의약조성물
EP1308155B1 (en) Injectable solution containing a colloid of iron and shark cartilage-derived chondroitin sulfate
EP0013625B1 (en) Solubilized thymidine composition and method of producing same
EP1620072B1 (en) Zinc-containing sustained-release composition, its preparation, and method for producing the same
JP2716497B2 (ja) ヘモグロビン コンプレツクス
EP2026789A2 (de) Neue, an der tumorphysiologie orientierte formulierung eines zytostatikums, insbesondere von cis-platin
JPS6340166B2 (Direct)